10月9日，Recursion Pharmaceuticals盘中上涨8.1%，报4.27美元/股，成交额6096.86万美元。
消息面上，公司与Tempus AI的合作协议调整持续引发市场分歧。SEC文件显示，Recursion被删除了为便利而单方面终止协议的权利，未来两年至多8400万美元的自主付款被替换为三年4200万美元的承诺付款，部分投资者担忧公司财务灵活性受限。与此同时，公司近期披露多笔内部人交易，董事Borgeson Blake于10月6日以4.84美元卖出5万股，董事HERSHBERG ROBERT亦卖出2.5万股，高管减持行为进一步压制了市场情绪。
Recursion Pharmaceuticals是一家临床阶段的TechBio公司，通过其递归操作系统整合超过50PB的专有数据，在湿实验室实验与干实验室计算工具之间形成迭代循环，用于识别、验证和转化治疗洞见。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.